Pay in 4 interest-free payments of $5.38 Learn more
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3
Their wide-ranging applications in disease prevention and treatment underscore their medical significance (65)
Retatrutide (LY3437943) is Eli Lillys experimental triple-agonist drug that activates: GLP-1 (Glucagon-like peptide-1) reduces appetite and slows digestion GIP (Glucose-dependent insulinotropic peptide) enhances insulin sensitivity Glucagon receptor increases fat metabolism and energy expenditure In phase-2 trials, Retatrutide achieved up to 24% body-weight reduction rivaling or even surpassing bariatric surgery outcomes
They cannot claim to deliver the same outcomes as FDA-approved GLP-1 drugs like Wegovy or Zepbound, Ventura tells TODAY.com
43 The focus should be on finding a starting point that feels achievable and building from there
